University of Vermont

College of Medicine

Vermont Cancer Center

trials_gastro.html

Gastrointestinal Cancer Clinical Trials

The Vermont Cancer Center has many trials specifically focused on gastrointestinal cancer research.

Status: Active - Recruiting
Study Title:
ACOSOG Study Z6051: A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Purpose:This randomized phase III trial is studying laparoscopic-assisted resection to see how well it works compared with open resection in treating patients with stage IIA, stage IIIA, or stage IIIB rectal cancer.
ClinicalTrials.gov Identifier: NCT00726622
Primary/Site/Co Investigator: Gino T. Trevisani, MD
Contact: Gino Trevisani (802) 847-3330
Information: http://www.clinicaltrials.gov/ct2/show/NCT00726622?term=ACOSOG&rank=10
Institution Number: M09-185
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
NCCTG 1048 – A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation  for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Purpose: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery.  Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy alone is more effective then chemotherapy plus radiation therapy in treating rectal cancer.
ClinicalTrials.gov Identifier: NCT01515787
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Karen Wilson (802) 656-4101
Information: http://www.clinicaltrials.gov/ct2/show/NCT01515787?term=NCCTG+1048&rank=1
Institution Number: CHRMS M13-118, NCCTG 1048
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
CALGB 80803 – Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Purpose: The purpose of this trial is to learn if we can improve the outcomes for patients with esophageal cancer by using PET/CT scans to determine whether or not a particular chemotherapy regimen is showing any effect on the tumor. We are trying to learn if PET/CT response can be used as a way to better direct therapy for esophageal tumors.
ClinicalTrials.gov Identifier: NCT01333033
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Karen Wilson (802) 656-4101

Information: http://www.clinicaltrials.gov/ct2/show/NCT01333033?term=CALGB+80803&rank=1

Institution Number: CHRMS M12-053, CALGB 80803
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
CALGB 80702 – A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Purpose: In this study, we will evaluate the effects (good and bad) of an oral drug called celecoxib when given in combination with FOLFOX chemotherapy.  In addition to evaluating the impact of celecoxib on lowering the risk of cancer recurrence, in this trial, we will study whether 6 treatments over 3 months are as effective as 12 treatments over 6 months and whether side effects can be reduced with fewer treatments.
ClinicalTrials.gov Identifier: NCT01150045
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Karen Wilson (802) 656-4101

Information: http://www.clinicaltrials.gov/ct2/show/NCT01150045?term=CALGB+80702&rank=1

Institution Number: CHRMS M12-054, CALGB 80702
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: RTOG 1201 – A Phase II Randomized Trial of High versus Standard Intensity Local or Systemic Therapy for Unresectable Pancreatic Cancer
Purpose: The purpose of this study is to compare the effects, good and/or bad, of three different ways to treat unresectable pancreatic cancer to determine if one increases survival better than another. All of the treatments used in this study include both chemotherapy and radiation therapy.   Group 1 uses standard chemotherapy with higher doses of radiation therapy; group 2 uses standard chemotherapy and standard doses of radiation therapy (considered to be standard of care); and group 3 uses a more intensified chemotherapy treatment program with standard radiation therapy doses. 
ClinicalTrials.gov Identifier: NCT01921751
Primary/Site/Co Investigator: Ruth Heimann, MD, PhD
Contact: Karen Wilson (802) 656-4101

Information: http://clinicaltrials.gov/ct2/show/NCT01921751?term=RTOG+1201

Institution Number: CHRMS M14-006 / RTOG 1201
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomized clinical study. 
Purpose: The purpose of this study is to find out if the combination of SIRT (Selective internal radiation therapy) and FOLFOX chemotherapy gives improved outcomes over FOLFOX chemotherapy alone for patients with colorectal cancer that has spread to the liver.  FOLFOX chemotherapy is the standard chemotherapy for colorectal cancer and consist of 3 drugs, folinic acid, fluorouracil and oxaliplatin. 
ClinicalTrials.gov Identifier: NCT01721954
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Kate Murray (802) 656-9401

Information: http://clinicaltrials.gov/ct2/show/NCT01721954?term=Sirtex&rank=1

Institution Number: M13-296
Protocol Research Type: Industry Sponsored
Status: Active - Closed to Accrual
Study Title:
VCC 0908 – Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen
Purpose: Severe nausea and/or vomiting in patients receiving radiotherapy to the upper abdomen is common despite having received pre-medication with ondansetron, a standard preventive treatment. This study aims to reduce the incidence of significant nausea and/or vomiting with the addition of the NK1-antagonist aprepitant to standard ondansetron treatment. This study will also assess the safety and tolerability of prolonged administration of aprepitant over the 4 to 6 week period of radiation treatment.
ClinicalTrials.gov Identifier: NCT00970905
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Karen Wilson (802) 656-4101

Information: http://www.clinicaltrials.gov/ct2/show/NCT00970905?term=Effectiveness+of+Aprepitant+in+Addition+to+Ondansetron+in+the+Prevention+of+Nausea+and+Vomiting&rank=1

Institution Number: M10-009
Protocol Research Type: Ops Center Enrolling

 

Last modified October 17 2014 03:28 PM